Generic drugs

Shares of generic and specialty medicines maker Teva Pharmaceutical Industries (NYSE: TEVA) fell more than 9 percent Monday morning in reaction to a lawsuit filed by 44 states. What Happened Teva, along with other global drug companies, is accused of conspiring to inflate the prices of their...

Retail pharmacy chain Rite Aid Corporation (NYSE: RAD) announced a renewal of its contract Wednesday with pharmaceutical distributor McKesson Corporation (NYSE: MCK) through 2029. What Happened McKesson will continue sourcing and offering Rite Aid delivery of branded and generic drugs...

The health care sector, the third-largest sector weight in the S&P 500, is surging. Generic drugmakers have been a source of strength for the group. For example, the VanEck Vectors Generic Drugs ETF (NASDAQ: GNRX) is up 9 percent since the start of 2018 and resides near all-time highs after...

Investors are hard pressed to find a standout in the specialty pharmaceutical space as many companies lack the "positive narrative" that can be found the rest of the biopharmaceutical space, analysts at Goldman Sachs said in an industry-wide report. The Analyst Goldman Sachs' Dana...

After a turbulent 2017, Mizuho analysts now see upside potential for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock. The Analyst Mizuho Securities USA's Irina Koffler upgraded Teva's stock rating from Neutral to Buy with a price target boosted from $16 to $23. The...

Mallinckrodt PLC (NYSE: MNK), a generic specialty pharmaceutical company, said Friday in an 8-K filing it expects to see an up to $500 million benefit from President Donald Trump's tax reform plan. What You Need To Know U.S. government officials passed this week the Tax Cut and Jobs Act and...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs. The Analyst Goldman Sachs' Jami Rubin upgraded Teva's stock from Neutral to Buy with...

Perrigo Company plc Ordinary Shares (NYSE: PRGO)'s business has faced multiple pressures, including industry-wide price erosion, a legal battle for possible collusion in generic drug pricing along with a management transition. At the same time, some analysts see the bullish case for owning the...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s third quarter earnings report disappointed investors, as it included another reduction to its full year 2017 earnings per share and revenue outlook. The Analyst JPMorgan's Chris Schott downgraded Teva's stock rating from Neutral...

Perrigo Company plc Ordinary Shares (NYSE: PRGO) impressed investors with third-quarter earnings Thursday and issued encouraging guidance that led some of Wall Street's bears to revisit their thesis on the pharmaceutical manufacturer.  The Analyst RBC Capital Markets' Randall...

Analysts at Deutsche Bank see a scenario in which Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock can move higher from its current levels but are simultaneously no longer recommending investors be buying the stock. The firm's Gregg Gilbert downgraded Teva's stock from Buy...

Adamas Pharmaceuticals Inc (NASDAQ: ADMS), a small-cap pharmaceutical company that develops therapies to treat chronic neurologic disorders, is a "misunderstood" stock that has a potential upside of four times, Kerrisdale Capital said in a new report. Adamas is expected to soon launch its first...

Shares of Endo International plc (NASDAQ: ENDP) traded as high as $6.94 Monday morning, but gave up some of the gains by the afternoon. The stock was still higher by more than 5 percent in reaction to the company's preliminary third-quarter results. Endo said on Monday it expects to report...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were under heavy selling pressure Wednesday morning after the U.S. Food and Drug Administration granted approval for a rival product. The FDA granted approval to Mylan N.V. (NASDAQ: MYL) to sell a generic version of Teva's Copaxone...

Shares of Mylan N.V. (NASDAQ: MYL) traded higher by more than 13 percent Wednesday morning after the U.S. Food and Drug Administration granted approval for the company's generic version of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s Copaxone. Copaxone, a therapy that is intended...